AbbVie

Predictability is solid for a pharma given diversified revenue streams and long-dated IP on its leading assets. 1H25 net revenues were about 28.8 billion dollars, up roughly 7 to 8 percent year over year, and gross margin ran ~71 percent, evidencing a high-quality mix. TTM FCF of ~18.2 billion dollars underscores resilience.

However, trial outcomes (e.g., VERONA negative in higher-risk MDS) and IRA dynamics inject volatility. The immunology base and chronic therapies create recurring demand, but pharma remains inherently less predictable than true tollbooth businesses.

Geographic and payer diversification are favorable, and near-to-mid term visibility is supported by extended Rinvoq protection and Skyrizi growth. Sources: AbbVie Q2 2025 10-Q; AbbVie Q1 2025 release; AbbVie Q2 2025 results page.